Print
New drug combination approved for treatment of BRCA-mutated metastatic prostate cancer
https://www.facingourrisk.org/XRAY/Akeega-for-BRCA-mutated-metastatic-prostate-cancer
Full article: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-niraparib-and-abiraterone-acetate-plus-prednisone-brca-mutated-metastatic-castration
The FDA approved Akeega (niraparib and abiraterone) plus prednisone for the treatment of BRCA-mutated, metastatic castration-resistant prostate cancer (mCRPC). Akeega can be used as an early or later treatment. (Posted 11/9/23)
Este artículo está disponible en español.
Questions To Ask Your Health Care Provider
- What stage is my prostate cancer?
- Is my prostate cancer castration-resistant?
- What options do I have for treating my prostate cancer?
- Should I have tumor testing or genetic testing?
- What side effects may occur with my cancer treatment?
Open Clinical Trials
The following studies look at PARP inhibitors and similar agents for treating people with advanced prostate cancer:
Other clinical trials for people with prostate cancer can be found here.
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.